Skip to content
Evigrade
CriticalHMG-CoA reductase inhibitor (statin)×Imidazole antifungal

Updated · Methodology

Mechanism

The enzyme CYP3A4 metabolises lovastatin, and drugs that inhibit this pathway can raise plasma lovastatin levels (lovastatin label, US Food and Drug Administration, FDA). Strong CYP3A4 inhibitors increase the risk of myopathy and rhabdomyolysis (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The miconazole oral gel SmPC calls miconazole a clinically potent CYP3A4 inhibitor. It lists lovastatin and simvastatin among the drugs that must not be combined with oral miconazole, because their levels rise and may cause rhabdomyolysis (miconazole oral gel SmPC, AEMPS). The documents give no study of this pair. Patients hold the gel in the mouth and then swallow it. After a 60 mg dose, plasma miconazole levels peak at 31–49 ng/mL, and the half-life is 20–25 hours (miconazole oral gel SmPC, AEMPS). Less than 1% of a cream dose is absorbed (miconazole cream SmPC, AEMPS). Each Spanish vaginal ovule contains 100 mg of miconazole with 300 mg of metronidazole. Their SmPC gives data for 1200 mg miconazole ovules: peak plasma levels more than 100 times lower than after oral or intravenous use (vaginal ovule SmPC, AEMPS).

Symptoms

Myopathy causes muscle pain, tenderness or weakness, with creatine kinase (CK) more than 10 times the upper limit of normal (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Myopathy sometimes progresses to rhabdomyolysis, a breakdown of muscle, with or without acute kidney failure caused by myoglobin in the urine. In rare cases it is fatal (lovastatin SmPC, AEMPS). Warning signs are unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin label, US Food and Drug Administration, FDA).

Management

The combination is contraindicated: the miconazole oral gel summary of product characteristics (SmPC) lists lovastatin among the drugs that must not be combined with oral miconazole (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The gel is held in the mouth and then swallowed, so the ban also applies when it is used for oral or oesophageal candidiasis (miconazole oral gel SmPC, AEMPS). The Spanish and US lovastatin labels contraindicate strong CYP3A4 inhibitors. Miconazole is not among their examples, but the gel SmPC itself calls miconazole a clinically potent inhibitor of this enzyme (lovastatin SmPC, AEMPS, and label, US Food and Drug Administration, FDA; miconazole oral gel SmPC, AEMPS). If a short course of a strong inhibitor is unavoidable, suspend lovastatin for the duration of that course (lovastatin FDA label). The Spanish lovastatin SmPC states this rule for itraconazole, ketoconazole, erythromycin, clarithromycin and telithromycin (lovastatin SmPC, AEMPS). The miconazole cream and vaginal ovule SmPCs do not mention statins: according to them, little miconazole reaches the blood and clinically relevant interactions are rare (miconazole cream and vaginal ovule SmPCs, AEMPS). Explain to the patient the risk of myopathy and its signs: unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin FDA label). If muscle pain, weakness or cramps appear, measure creatine kinase (CK). Stop lovastatin if CK is above 5 times the upper limit of normal without strenuous exercise or if myopathy is suspected. With severe muscle symptoms, consider stopping lovastatin even at a lower CK (lovastatin SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Lovastatin

Other interactions with Miconazole